[IV iron or oral iron in anaemic patient with CKD].
Population-based study demonstrated that iron deficiency is really frequent, and anaemia not rare. Nevertheless, iron deficiency afflicts anaemic patients at all stages of chronic kidney disease (CKD). Bioavailability of oral iron supplements is highly variable, particularly in case of CKD. Moreover, efficacy is in favour of intravenous (i.v.) iron over oral iron. And safety of i.v. iron sucrose is today definite. Finally, recommended targets, i.e. Hb > 11 g/dl and transferring saturation > 20%, necessitate i.v. iron.
Frimat
Luc
L
Service de néphrologie, CHU de Nancy, 29, avenue du Maréchal-de-Lattre-de-Tassigny, 54035 Nancy. l.frimat@chu-nancy.fr
Thilly
Nathalie
N
Boini
Stéphanie
S
D000284:Administration, Oral; D000740:Anemia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D001682:Biological Availability; D019587:Dietary Supplements; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage* / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications*; D015995:Prevalence
D007501:Iron